Leaders in Pharmaceutical Business Intelligence (LPBI) Group

9:15AM – 9/30/2014: Public Markets and M&A  @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Reporter: Aviva Lev-Ari, PhD, RN

 

Real Time Media Conference Coverage  –  Business and Scientific Channels by: http://pharmaceuticalintelligence.com

9:30AM – Keynote Speech by Anthony Rosenberg, Head of Business Development and Licensing, Novartis Pharma AG – “Global M&A: a Novartis Perspective” 

Chaired by: 

• Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners

Presenting the panel.

Biotech sector, since 1/103, 30% increase, European Biotech up 72%, US Biotech up 100%. Large deals,

Summarizing at 10AM: Is it critical for the US to be engaged in inversion of taxation.

Panelists: 

• David Colpman, Former Head Global Business Development at Shire

New CEO, new leadership, six companies were bought, major product for Dry eye and fibrosis. Among the strongest prospects in the industry. Tax inversion an issue in the industry. Pfizer and AstraZeneca no deal.

• Marco Superina, Head M&A Switzerland, Head of Healthcare M&A Europe, Credit Suisse AG

Inversions: Europe Pfizer and AstraZeneca — trends of inversion will continue, platform to encourage acquisitions, In the US the inversion transaction allows US firms to lower taxes in the US, from 30% lowered to less than 20%. Irish companies are to benefit from trends in inversion of taxtion. NOTICE on Inversion: spin off qualifications addressed, US is to change the rules, raise awareness before election in the US.

• Michael Shalmi, Senior Partner, Novo A/S

Management of wealth of the Foundation, 4 Billion Euro, portfolio of life Sciences 36 Billion entity, controlled shared programs, Venture investment in US and in Europe, commercialization of innovations, visit core strategy, larger entities acquired. Private and Public, resilience to changes. In 2002 the market value kept growing, technology fast pace to continue.

– Hearing Instrument Market: Dispensing, consolidated

– Component Market – Two players, Sonion acquired strong operational performance

Size: after a certain size it does not matter

• Kai Brüning, Senior Portfolio Manager, IPO Asset Management GmbH

Asset management – part insurance management of Pension funds and part pharmaceutical, central banks push investment comunity to get 4% very good environment, P/E multiples 20, broad market 17, HealthCare requires Premium, Big Pharmas have +20% multiples, US invests in insurance, in Europe the investment is in Bonds, not allowed to invest in riskier deals.

Market making: the Bankers, smart investors, no commission paid, if allocation comes from the US, Anglo American market domination vs. far east involvement.

• Tim Mitchell, CEO, Sareum Ltd.

based in Cambridge, UK. Three programs, Oncology and two preclinical. funding gap alternative financing. US and China involvement, previous moth trading determines the cash requirements for the near future.

• Sascha Alilovic, VP MorphoSys

90 compounds, internal development vs acquisition, able yo generate 100 million propitiatory pipeline – without a need to go to the stock market,

Biotech needs understanding of valuation, being listed on the stock exchange in the US, 1 Billion valuation, US must play due to high taxation.

• Nicolas Franco, Actelion Pharmaceutical

Launched Phased III prospects from injectable to oral. The market is more competitive, IPOs vs. Deals in the market, why sell assets, if the option of value inflection point is an option. Licensing is still an option

#startup#biotech #pharmanews

@SachsAssociates@pharma_BI @BiotechNews